{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:46:50Z","timestamp":1790210810669,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jhep.2016.05.016","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T08:48:26Z","timestamp":1463820506000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":171,"title":["Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B"],"prefix":"10.1016","volume":"65","author":[{"given":"Anna S.","family":"Lok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven-Huy B.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy N.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Jeffrey","family":"Fessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Rodell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Massetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.05.016_b0005","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.05.016_b0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.05.016_b0015","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.05.016_b0020","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.05.016_b0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.05.016_b0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.016_b0035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/jmv.20935","article-title":"Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance","volume":"79","author":"Hou","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2016.05.016_b0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.05.016_b0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"36","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.016_b0050","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/j.1365-2893.2011.01509.x","article-title":"Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B","volume":"19","author":"Kwon","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.05.016_b0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcv.2009.07.005","article-title":"Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B","volume":"46","author":"Tangkijvanich","year":"2009","journal-title":"Clin Virol"},{"key":"10.1016\/j.jhep.2016.05.016_b0060","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jmv.22089","article-title":"Correlation of serum hepatitis B surface antigen level with response to entecavir in na\u00efve patients with chronic hepatitis B","volume":"83","author":"Lee","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2016.05.016_b0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-\u03b12a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.016_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350701200107","article-title":"Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels","volume":"12","author":"Manesis","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.05.016_b0075","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/vir.0.81920-0","article-title":"The immune response during hepatitis B virus infection","volume":"87","author":"Bertoletti","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2016.05.016_b0080","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.016_b0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/jhep.2000.19324","article-title":"Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms","volume":"32","author":"Webster","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.016_b0090","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"12","author":"Vandepapeliere","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.05.016_b0095","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/AAC.00276-09","article-title":"Randomized controlled study investigating viral suppression and serological response following pre-S1\/pre-S2\/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B","volume":"53","author":"Hoa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.05.016_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/8b913538-74f4-4560-b700-0936a8e35847","article-title":"A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.016_b0105","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.05.016_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime \u2013 Adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2016.05.016_b0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.510300208","article-title":"A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus","volume":"30","author":"Heathcote","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.016_b0120","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2016.05.016_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101904","article-title":"A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance","volume":"9","author":"King","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2016.05.016_b0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/87974","article-title":"Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity","volume":"7","author":"Stubbs","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2016.05.016_b0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","article-title":"Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B","volume":"16","author":"Chan","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.05.016_b0140","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.05.016_b0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cis859","article-title":"Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816302021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T05:39:52Z","timestamp":1656481192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816302021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0168827816302021"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.016","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}